Clostridium difficile Infection

Medical Clinics of North America

Volumn 97, Issue 4, 2013, Pages 523-536

  Knight, Christopher L ^a   Surawicz, Christina M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium difficile; Fecal microbiota transplantation; Metronidazole

Indexed keywords

FIDAXOMICIN; GLUTAMATE DEHYDROGENASE; LOPERAMIDE; METRONIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFAMPICIN; VANCOMYCIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC THERAPY; ASCITES; BACTERIAL TRANSMISSION; CLOSTRIDIUM DIFFICILE INFECTION; COLON PERFORATION; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG COST; ENDOSCOPY; ENTERITIS; ENZYME IMMUNOASSAY; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; HEALTH CARE; HOSPITAL INFECTION; HUMAN; HYPOALBUMINEMIA; ILEUS; LACTATION; LEUKOCYTOSIS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RECURRENT INFECTION; REVIEW; RISK FACTOR; STOMACH ACID; STOMACH ACID SECRETION; TOXIC MEGACOLON; TREATMENT DURATION; ULCERATIVE COLITIS;

ANTI-BACTERIAL AGENTS; ANTIDIARRHEALS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; HUMANS; PROBIOTICS; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84879787160     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.02.003     Document Type: Review

References (66)

1. Kuipers E.J., Surawicz C.M. Clostridium difficile infection. Lancet 2008, 371(9623):1486-1488.
2. Lessa F.C., Gould C.V., McDonald L.C. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012, 55(Suppl 2):S65-S70.
3. Riegler M., Sedivy R., Pothoulakis C., et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium invitro. JClin Invest 1995, 95(5):2004-2011.
4. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. NEngl J Med 2005, 353(23):2433-2441.
5. Zilberberg M.D., Shorr A.F., Kollef M.H. Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000-2005. Emerg Infect Dis 2008, 14(6):929-931.
6. Diggs N.G., Surawicz C.M. Clostridium difficile infection: still principally a disease of the elderly. Therapy 2010, 7(3):295-301.
7. Garey K.W., Jiang Z.-D., Yadav Y., et al. Peripartum Clostridium difficile infection: case series and review of the literature. Am J Obstet Gynecol 2008, 199(4):332-337.
8. Unger J.A., Whimbey E., Gravett M.G., et al. The emergence of Clostridium difficile infection among peripartum women: a case-control study of a C. difficile outbreak on an obstetrical service. Infect Dis Obstet Gynecol 2011, 2011:267249.
9. Centers for Disease Control and Prevention CDC Surveillance for community-associated Clostridium difficile-Connecticut, 2006. MMWR Morb Mortal Wkly Rep 2008, 57(13):340-343.
10. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006, 145(10):758-764.
11. Owens R.C., Donskey C.J., Gaynes R.P., et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008, 46(Suppl 1):S19-S31.
12. Hensgens M.P., Goorhuis A., Dekkers O.M., et al. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. JAntimicrob Chemother 2012, 67(3):742-748.
13. Vesteinsdottir I., Gudlaugsdottir S., Einarsdottir R., et al. Risk factors for Clostridium difficile toxin-positive diarrhea: a population-based prospective case-control study. Eur J Clin Microbiol Infect Dis 2012, 31(10):2601-2610.
14. Kutty P.K., Woods C.W., Sena A.C., et al. Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 2010, 16(2):197-204.
15. Bavishi C., Dupont H.L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011, 34(11-12):1269-1281.
16. Howell M.D., Novack V., Grgurich P., et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010, 170(9):784-790.
17. Deshpande A., Pant C., Pasupuleti V., et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012, 10(3):225-233.
18. Janarthanan S., Ditah I., Adler D.G., et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012, 107(7):1001-1010.
19. Kwok C.S., Arthur A.K., Anibueze C.I., et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012, 107(7):1011-1019.
20. Rodemann J.F., Dubberke E.R., Reske K.A., et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5(3):339-344.
21. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008, 14(10):1432-1442.
22. Dansinger M.L., Johnson S., Jansen P.C., et al. Protein-losing enteropathy is associated with Clostridium difficile diarrhea but not with asymptomatic colonization: a prospective, case-control study. Clin Infect Dis 1996, 22(6):932-937.
23. Fujitani S., George W.L., Murthy A.R. Comparison of clinical severity score indices for Clostridium difficile infection. Infect Control Hosp Epidemiol 2011, 32(3):220-228.
24. Wanahita A., Goldsmith E.A., Marino B.J., et al. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med 2003, 115(7):543-546.
25. Planche T., Wilcox M. Reference assays for Clostridium difficile infection: one or two gold standards?. JClin Pathol 2011, 64(1):1-5.
26. Planche T., Aghaizu A., Holliman R., et al. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008, 8(12):777-784.
27. Shetty N., Wren M.W., Coen P.G. The role of glutamate dehydrogenase for the detection of Clostridium difficile in faecal samples: a meta-analysis. JHosp Infect 2011, 77(1):1-6.
28. Deshpande A., Pasupuleti V., Rolston D.D., et al. Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: a meta-analysis. Clin Infect Dis 2011, 53(7):e81-e90.
29. Boyanton B.L., Sural P., Loomis C.R., et al. Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection. JClin Microbiol 2012, 50(3):640-645.
30. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31(5):431-455.
31. Surawicz C.M., McFarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000, 31(4):1012-1017.
32. Wilcox M.H., Freeman J., Fawley W., et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. JAntimicrob Chemother 2004, 54(1):168-172.
33. Climo M.W., Israel D.S., Wong E.S., et al. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998, 128(12 Pt 1):989-995.
34. Valiquette L., Cossette B., Garant M.-P., et al. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated diseasecaused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007, 45(Suppl 2):S112-S121.
35. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007, 44(2):159-177.
36. Wullt M., Odenholt I., Walder M. Activity of three disinfectants and acidified nitrite against Clostridium difficile spores. Infect Control Hosp Epidemiol 2003, 24(10):765-768.
37. Johnson S., Gerding D.N., Olson M.M., et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990, 88(2):137-140.
38. Mayfield J.L., Leet T., Miller J., et al. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis 2000, 31(4):995-1000.
39. Wilcox M.H., Fawley W.N., Wigglesworth N., et al. Comparison of the effect of detergent versus hypochlorite cleaning on environmental contamination and incidence of Clostridium difficile infection. JHosp Infect 2003, 54(2):109-114.
40. Johnston B.C., Ma S.S., Goldenberg J.Z., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012, 157(12):878-888.
41. Bolton R.P., Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986, 27(10):1169-1172.
42. Kapoor K., Chandra M., Nag D., et al. Evaluation of metronidazole toxicity: a prospective study. Int J Clin Pharmacol Res 1999, 19(3):83-88.
43. Nerandzic M.M., Mullane K., Miller M.A., et al. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 2012, 55(Suppl 2):S121-S126.
44. Finegold S.M., Molitoris D., Vaisanen M.L., et al. Invitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrobial Agents Chemother 2004, 48(12):4898-4902.
45. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. NEngl J Med 2011, 364(5):422-431.
46. Pepin J., Valiquette L., Gagnon S., et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007, 102(12):2781-2788.
47. Zar F.A., Bakkanagari S.R., Moorthi K.M., et al. Acomparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45(3):302-307.
48. Drekonja D.M., Butler M., MacDonald R., et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 2011, 155(12):839-847.
49. Al-Nassir W.N., Sethi A.K., Nerandzic M.M., et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008, 47(1):56-62.
50. Musher D.M., Aslam S., Logan N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005, 40(11):1586-1590.
51. Apisarnthanarak A., Razavi B., Mundy L.M. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002, 35(6):690-696.
52. Markelov A., Livert D., Kohli H. Predictors of fatal outcome after colectomy for fulminant Clostridium difficile Colitis: a 10-year experience. Am Surg 2011, 77(8):977-980.
53. Ali S.O., Welch J.P., Dring R.J. Early surgical intervention for fulminant pseudomembranous colitis. Am Surg 2008, 74(1):20-26.
54. Butala P., Divino C.M. Surgical aspects of fulminant Clostridium difficile colitis. Am J Surg 2010, 200(1):131-135.
55. Barbut F., Richard A., Hamadi K., et al. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. JClin Microbiol 2000, 38(6):2386-2388.
56. Kyne L., Warny M., Qamar A., et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357(9251):189-193.
57. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97(7):1769-1775.
58. Garey K.W., Ghantoji S.S., Shah D.N., et al. Arandomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. JAntimicrob Chemother 2011, 66(12):2850-2855.
59. Curry S.R., Marsh J.W., Shutt K.A., et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009, 48(4):425-429.
60. Bakken J.S., Borody T., Brandt L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011, 9(12):1044-1049.
61. Gough E., Shaikh H., Manges A.R. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011, 53(10):994-1002.
62. van Nood E., Vrieze A., Nieuwdorp M., et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. NEngl J Med 2013, 368(5):407-415.
63. Oral vancomycin followed by fecal transplant versus tapering oral vancomycin. Available at: Accessed on December 15, 2012. http://clinicaltrials.gov.
64. Fecal transplant for relapsing C. difficile infection. Available at: Accessed on December 15, 2012. http://clinicaltrials.gov.
65. McFarland L.V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010, 16(18):2202-2222.
66. Enache-Angoulvant A., Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005, 41(11):1559-1568.